PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy - Wikidata - awgldk - TriplyDB

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

http://www.wikidata.org/entity/Q34186755

about

A novel classification of lung cancer into molecular subtypes Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis The study of the relation of DNA repair pathway genes SNPs and the sensitivity to radiotherapy and chemotherapy of NSCLC A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations Association of mTOR polymorphisms with cancer risk and clinical outcomes: a meta-analysis.Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer Association between AKT1 Gene Polymorphism rs2498794 and Smoking-Related Traits with reference to Cancer Susceptibility.Genetic association between PIK3CA gene and oral squamous cell carcinoma: a case control study conducted in Chongqing, China Genetic variations in the PI3K-PTEN-AKT-mTOR pathway are associated with distant metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.Association between eIF3α polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients Fine mapping of type 1 diabetes regions Idd9.1 and Idd9.2 reveals genetic complexity.MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes.The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling.Targeting the PI3K pathway for cancer therapy.The potential anticancer effect of beta-blockers and the genetic variations involved in the interindividual difference.Association Between Genetic Variants of Akt1 and Endometrial Cancer.Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.Association of genetic variations in mTOR with risk of childhood acute lymphoblastic leukemia in a Chinese population.Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population.Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients.Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery.PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy.Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population.

P2860

Q28731874-2099DBB2-53BA-467B-BBF3-6F8B126BABD2 Q29248629-63FC4F03-53E9-43CF-B8DD-49DE440A9217 Q30381884-5F5B7AB2-E1BA-4179-949B-54504FF3F664 Q34653205-5C3B4A36-F57F-42CE-916A-99337DE8316A Q35036471-5EB006B6-E5EE-40CF-9872-310B54CBBB56 Q35166585-142BA293-AD3A-4186-A4EB-7051F7AF3E85 Q35562928-EF1B5725-AE3E-40D5-82EB-A699DE771F00 Q35763163-4215C86D-52E0-4548-BA2C-1D1F79B5B450 Q35883001-2473BA3B-3183-480C-B196-90BC11548DAA Q36201710-7A6B91B2-14A8-4AA7-82B5-638C1CB53E82 Q36477469-D7096EFF-D8A9-4446-A68B-6DE20F4B82A8 Q36629248-DE7C8C15-F8A2-4FCD-ADFB-6CD51FA3F1EC Q37300049-2AFBDCF8-0BFB-420B-9A5E-758A7122D61F Q37661175-3C00E2AA-86E5-411D-B00B-C73723E139E8 Q37746303-AFCAA07E-B92C-411F-95F8-EA735A014FE1 Q37871915-58A44188-8821-4957-866A-EAF4E3FD86D2 Q38017247-BAFA5BBB-0ABB-4DFC-8427-B9CDA8F54FFC Q38019609-338EB59C-FF49-42CA-94A5-B5B8680484C9 Q38664877-2E2BA665-424E-4046-A645-8BFD25364DAB Q41039508-8153B4A9-905F-4338-90CE-874FCA54E61D Q41487456-F59DA26F-57FB-4A2C-BD12-A582AEE50234 Q42224250-8FD95EFC-19B3-4067-AB20-773560398872 Q42634827-057204F2-7CA8-4D65-9112-E4FFB521A969 Q44435172-E17A92CA-7F10-412D-B012-38EC2ED39702 Q45254443-2C910593-D49C-4C18-B314-31CEAA5ECEAC Q47120813-585444B7-FF3E-43B1-BEBA-57B5FEFE1360 Q52629228-1125B02F-02B8-446B-AB98-8F47A01C5C57 Q54227938-C54D8FB4-9F3A-42FE-904A-386271568CDC Q54318640-8C7AF735-0E1C-43FE-A5AE-BB2A7F5822AA Q55072692-320B6F90-7075-4326-8192-7B60BC549651

P2860

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

http://www.wikidata.org/entity/Q34186755

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@ast

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@en

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@nl

type

label

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@ast

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@en

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@nl

prefLabel

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@ast

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@en

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@nl

P1433

Q34186755-3B08432E-249F-4F55-BE69-0C9E1334A7D8

P1476

Q34186755-89889191-1C0C-4A83-88AC-D3756A11410A

P2093

Q34186755-0D131F40-FCAB-4917-A3D1-5062E7143CA7

Q34186755-2D3A8809-A993-49AB-80DC-6A67149C3753

Q34186755-469C2E2D-5970-4B93-9123-11ACA17B7FC6

Q34186755-59EB45E8-D5C3-4DC5-A532-3EB03B05F942

Q34186755-63A78CFC-B140-4BE6-9629-5150418D2F71

Q34186755-883F623A-CB44-4A81-B4EF-DE07F9B35AA8

Q34186755-D821932C-13B0-4AD3-B2C7-D7CD5C959D97

Q34186755-F562DF5E-7F6F-44FD-98CC-B11685C009F5

P2860

Q34186755-09A87C8C-B112-4CCE-A73C-046151C47DBE

Q34186755-172ED21A-16BC-4B6F-B931-C46E2FCA5DAB

Q34186755-1E581A5F-B869-4F9A-86C1-2B5F8CA311DC

Q34186755-35AB4ECC-AB5B-41C7-B4BF-FC9F1C8CE1D6

Q34186755-381670C4-93AE-44A0-99F2-5119D4F15D5A

Q34186755-3933044F-268F-4A03-93A7-FEBAF0B4205B

Q34186755-3E211271-71E2-474B-83FD-D65791E5088A

Q34186755-422C4600-1B28-44FF-ADE8-01996846414C

Q34186755-43E709C6-BAF9-46E4-AB09-25B447DC708E

Q34186755-46421E36-8AA4-4F62-9A4C-B2379D56C08F

P304

Q34186755-ABE7D0DE-1E24-43F0-842C-5B6F0EB872A6

P31

Q34186755-7B4DFAB2-3912-4111-86CF-786C53443A17

P356

Q34186755-8CA2A0A1-268B-4EA5-B611-4F7E58A576EF

P433

Q34186755-AFDFB161-5A53-478E-B6C1-A5993AA034B6

P478

Q34186755-4646CBF3-C10E-47EC-AAC6-5D4BACDE065F

P50

Q34186755-44BC5C6D-6055-4534-9CC3-4C8679466533

P577

Q34186755-A4EC1BEC-5D6D-4A69-8937-C60D9CFD29A8

P5875

Q34186755-144DDC91-E6BB-43F5-A705-1B99A0BBECAC

P698

Q34186755-9F0A9505-37BB-4D56-BCD9-4569EA97DDBA

P921

Q34186755-CD90522E-B9C1-4C94-9628-2365BBA9CE8B

P932

Q34186755-5B1D1F8E-120B-4AC8-9878-C0B65B159330

P356

J.LUNGCAN.2010.04.008

P1433

P1476

PI3K/PTEN/AKT/mTOR pathway gen ...... ng platinum-based chemotherapy

@en

P2093

Charles Lu

http://www.w3.org/2001/XMLSchema#string

David J Stewart

http://www.w3.org/2001/XMLSchema#string

Jie Lin

http://www.w3.org/2001/XMLSchema#string

Margaret R Spitz

http://www.w3.org/2001/XMLSchema#string

Michelle A T Hildebrandt

http://www.w3.org/2001/XMLSchema#string

Xia Pu

http://www.w3.org/2001/XMLSchema#string

Xifeng Wu

http://www.w3.org/2001/XMLSchema#string

Yuanqing Ye

http://www.w3.org/2001/XMLSchema#string

P2860

AKT/PKB signaling: navigating downstream

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

Mutation analysis of the PTEN/MMAC1 gene in lung cancer

The protein kinase B/Akt signalling pathway in human malignancy

Cancer statistics, 2009

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Exploiting the PI3K/AKT pathway for cancer drug discovery

Cisplatin: mode of cytotoxic action and molecular basis of resistance

PI3K pathway alterations in cancer: variations on a theme

Toxicity and response criteria of the Eastern Cooperative Oncology Group

P304

82-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2010.04.008

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44578160

http://www.w3.org/2001/XMLSchema#string

P698

20447721

http://www.w3.org/2001/XMLSchema#string

P921

P932

2952281

http://www.w3.org/2001/XMLSchema#string